1921
Volume 97, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Mass administration of azithromycin (MDA) is integral to trachoma control. Recent studies suggest that MDA may increase drug-resistant pathogens, yet findings from prior studies suggest little long-term impact on resistance. This disparity may be linked to differences in pre-MDA community-level resistance patterns. We describe carriage prevalence and antibiotic resistance patterns for (Spn) (nasopharyngeal swab collection), (SA) (nasopharyngeal swabs), and (EC) (rectal swabs) in 1,047 children ages 1–59 months in a district with MDA cessation 4 years ago. Antibiotic susceptibility was evaluated by disk diffusion and Etest. The carriage rates for Spn, SA, and were 43.5% (455/1,047), 13.2% (138/1,047), and 61.7% (646/1,047), respectively. Resistance to AZM was observed in 14.3%, 29.0%, and 16.6% of the Spn, SA, and EC isolates, respectively. Spn resistance was variable (0–67%) by hamlet. Future analyses will assess the influence of pre-MDA antibiotic resistance patterns on those observed following MDA.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.17-0022
2017-09-07
2018-09-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/97/3/tpmd170022.html?itemId=/content/journals/10.4269/ajtmh.17-0022&mimeType=html&fmt=ahah

References

  1. Gray GC, McPhate DC, Leinonen M, Cassell GH, Deperalta EP, Putnam SD, Karcher JA, Sawyer MH, Laurila A, Connor JD, , 1998. Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease. Clin Infect Dis 26: 103110.
  2. Fry AM, Jha HC, Lietman TM, Chaudhary JS, Bhatta RC, Elliott J, Hyde T, Schuchat A, Gaynor B, Dowell SF, , 2002. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis 35: 395402.
  3. Coles CL, Levens J, Seidman JC, Mkocha H, Munoz B, West S, , 2012. Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children. Pediatr Infect Dis J 31: 341346.
  4. Haug S, ., 2010. The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis 51: 571574.
  5. Coles CL, Mabula K, Seidman JC, Levens J, Mkocha H, Munoz B, Mfinanga SG, West S, , 2013. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clin Infect Dis 56: 15191526.
  6. West SK, Munoz B, Weaver J, Mrango Z, Dize L, Gaydos C, Quinn TC, Martin DL, , 2016. Can We Use Antibodies to Chlamydia trachomatis as a Surveillance Tool for National Trachoma Control Programs? Results from a District Survey. PLoS Negl Trop Dis 10: e0004352.
  7. CLSI, 2014. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. Wayne, PA: CLSI document M100-S24.
  8. Seidman JC, Coles CL, Silbergeld EK, Levens J, Mkocha H, Johnson LB, Munoz B, West SK, , 2014. Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control. Int J Epidemiol 43: 11051113.
  9. Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Mouton JW, Osterlund A, Rodloff A, Steinbakk M, Urbaskova P, Vatopoulos A, , 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 52: 145148.
  10. Leach AJ, Shelby-James TM, Mayo M, Gratten M, Laming AC, Currie BJ, Mathews JD, , 1997. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 24: 356362.
  11. Batt SL, Charalambous BM, Solomon AW, Knirsch C, Massae PA, Safari S, Sam NE, Everett D, Mabey DC, Gillespie SH, , 2003. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 47: 27652769.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0022
Loading
/content/journals/10.4269/ajtmh.17-0022
Loading

Data & Media loading...

  • Received : 10 Jan 2017
  • Accepted : 05 May 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error